Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Rhea-AI Summary

Altimmune (Nasdaq: ALT) announced that data from its Phase 2 MRI-based body composition sub-study of pemvidutide in overweight and obese subjects will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid. Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, is being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH) treatment.

The presentation, titled 'Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity,' will be given by Dr. Sarah Browne on September 10, 2024. Pemvidutide has shown promising results in clinical trials, demonstrating significant weight loss, reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. The FDA has granted Fast Track designation for pemvidutide in MASH treatment.

Positive

• Pemvidutide shows promising results in preserving lean body mass during weight loss
• FDA granted Fast Track designation for pemvidutide in MASH treatment
• Clinical trials demonstrate significant weight loss and improvements in metabolic markers
• Presentation at a major diabetes conference indicates growing interest in the treatment

Negative

• None.

News Market Reaction

-4.78%

1 alert

-4.78% News Effect

On the day this news was published, ALT declined 4.78%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60^th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Details for the presentations are as follows:

Title:	Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study (Session 038, Oral Presentation 557)
Presenter:	Sarah Browne, M.D., Vice President, Clinical Development, Altimmune
Date/Time:	Tuesday, September 10, 2024, at 1:45 pm CEST

About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

FAQ

What is pemvidutide and what is it being developed for by Altimmune (ALT)?

Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist being developed by Altimmune (ALT) for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).

When and where will Altimmune (ALT) present pemvidutide clinical data?

Altimmune (ALT) will present pemvidutide clinical data at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain, on September 10, 2024.

What are the key findings from pemvidutide clinical trials by Altimmune (ALT)?

Clinical trials of pemvidutide by Altimmune (ALT) have shown compelling weight loss, reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. It also preserves lean body mass during weight loss in overweight and obese patients.

Has pemvidutide received any special designations from the FDA for Altimmune (ALT)?

Yes, the U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) for Altimmune (ALT).